All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the MPN Hub spoke with Laura Michaelis, Medical College of Wisconsin, Milkwaukee, US. We asked, How did newer prognostic models change treatment algorithms in primary and secondary MF?
How did newer prognostic models change treatment algorithms in primary and secondary MF?
Michaelis discusses prognostic models in myelofibrosis such as the International Prognostic Scoring System (IPSS).
Myeloproliferative neoplasms, thrombosis, and COVID-19
Myeloproliferative neoplasms (MPN) are associated with a high prevalence of thrombosis at diagnosis: 28.6% in polycythemia vera (PV), 20.7% in essential thrombocytosis, and 9.5% in...
Thiotepa–busulfan–ﬂudarabine conditioning regimen in myeloﬁbrosis
For patients with myeloﬁbrosis (MF), allogeneic hematopoietic cell transplantation (allo-HCT) is still the only potential curative approach, but no consensus exists on the optimal...
Subscribe to get the best content related to MPN delivered to your inbox